Bayer: New data shows positive effect of kidney disease treatment drug

[August 29, 2022]  BERLIN (Reuters) - Bayer said that new data presented on Monday highlighted the potential of finerenone, compared with a placebo, to reduce the incidence of sudden cardiac death in a broad range of patients, including early and late stages of chronic kidney disease associated with type 2 diabetes.

(Writing by Miranda Murray; Editing by Paul Carrel)

[© 2022 Thomson Reuters. All rights reserved.] 

This material may not be published, broadcast, rewritten or redistributed.  Thompson Reuters is solely responsible for this content.

Bayer logo in Leverkusen, Germany, 27. February 2019. REUTERS/Wolfgang Rattay